News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PAION AG Release: Recruitment of Phase II/III Study With Short-Acting Anaesthetic/Sedative Remimazolam (Ono's Development Code: ONO-2745) in Japan is Completed



5/8/2013 9:57:37 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Aachen (Germany), 08 May 2013 - The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, General Standard: PA8) today announces that its partner, Ono Pharmaceutical Co., Ltd. ('ONO') has published, that the recruitment of the Phase II/III study with Remimazolam for general anaesthesia is completed. Remimazolam was administered during anaesthesia to 375 surgery patients.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
PAION AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES